POSA39 Cost-Effectiveness Analysis of Nivolumab for the Adjuvant Treatment of Patients with Resected Esophageal Cancer (EC) or Gastroesophageal Junction Cancer (GEJC) in Canada
Jan 1, 2022, 00:00 AM
10.1016/j.jval.2021.11.185
https://www.valueinhealthjournal.com/article/S1098-3015(21)01980-X/fulltext
Section Title :
Section Order :
10955
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)01980-X&doi=10.1016/j.jval.2021.11.185